Nigerian Firm, Ash Biomedical, Produces Seven Medications for HIV, Malaria, Hepatitis, Pregnancy
Adedayo Akinwale in Abuja A Nigerian firm, Ash Biomedical Diagnostics Ltd., has announced the production of seven of its own-brand diagnostic medicine to manage and treat HIV, malaria, hepatitis, and
Nigerian biomedical company Ash Biomedical Diagnostics Ltd. has unveiled seven new diagnostic medicines to combat HIV, malaria, hepatitis, and pregnancy. The company's Managing Director, Adetoyese Shodeinde, revealed that the products span four critical healthcare testing areas and comprise 12 Stock Keeping Units (SKUs). These include ABD HIVChek, MalChek, MalChek Plus, HepaQuik, HepaQuik Duo, PregSure, and FlaviQuik.
Shodeinde emphasized that this milestone reflects years of investment in quality, regulatory compliance, and product development. The newest additions, FlaviQuik and HepaQuik Duo, are designed for rapid Hepatitis C testing and dual screening for Hepatitis B and C, respectively. These additions support healthcare providers in identifying individuals who may require further medical evaluation during a single patient encounter.
Shodeinde highlighted that the milestone signifies progress in strengthening confidence in locally developed healthcare solutions and expanding access to rapid diagnostics. He added that the company's vision extends beyond producing diagnostic kits, aiming to build confidence in Nigerian healthcare manufacturing through quality, reliability, and national regulatory approval.
Written by urgent.news from This Day's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
